- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00304330
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients
June 11, 2018 updated by: University of Pittsburgh
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population
The information collected will provide insight in to the epidemiology of antibiotic resistance in a transplant compared to a non-transplant population.
Data is needed regarding the date of admission, date of bloodstream infection and location of ward/ICU so trends in the emergence of resistance and antibiotic usage can be detected.
Study Overview
Status
Completed
Conditions
Detailed Description
We need to collect details on the demographics (age, sex etc), underlying conditions, transplant types and immunosuppression, in-hospital antibiotic management and clinical outcomes so that the effect of antibiotic resistance on patient outcome can be measured.
We also need to collect microbiology and pathology data to determine the antibiotic susceptibility profile of the involved organisms.
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, prophylactic antimicrobials, physical exam findings, laboratory and radiographical data, empiric antimicrobial usage, microbiological data and resistance patterns, choice of antibiotic once organism identified, suspected source of infection, microbiological and clinical outcomes, laboratory results, demographic information, medications, gender, weight, ethnicity, and past medical history
Study Type
Observational
Enrollment (Actual)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
gram negative organisms
Description
Inclusion Criteria:
- All patients with a positive blood culture isolate growing a gram-negative organism will be included from 1996 - 2005
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
March 15, 2006
First Submitted That Met QC Criteria
March 15, 2006
First Posted (Estimate)
March 17, 2006
Study Record Updates
Last Update Posted (Actual)
June 12, 2018
Last Update Submitted That Met QC Criteria
June 11, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB# 0602123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gram Negative Infection
-
PfizerAllerganTerminatedGram-negative Bacterial InfectionUnited States, Hungary, Slovakia, Taiwan, India, Estonia, Greece, Italy
-
PfizerCompletedGram-negative Bacterial InfectionAustralia
-
Seoul National University HospitalCompletedMultidrug-resistant Gram-negative Bacteria InfectionKorea, Republic of
-
UMC UtrechtZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedInfection Resistant to Drugs | Gram-Negative Bacterial InfectionNetherlands
-
PfizerAbbVieNot yet recruiting
-
Merck Sharp & Dohme LLCCompletedSuspected or Documented Gram-negative Bacterial InfectionUnited States, Bulgaria, Chile, Colombia, Estonia, France, Greece, Hungary, Israel, Mexico, Norway, Philippines, Poland, Russian Federation, South Africa, Spain, Turkey, Ukraine
-
Merck Sharp & Dohme LLCCompletedSuspected or Documented Gram-negative Bacterial InfectionUnited States, Bulgaria, Colombia, Greece, Norway, Poland, Ukraine, United Kingdom
-
Ain Shams UniversityCompletedGram-Negative InfectionsEgypt
-
Cubist Pharmaceuticals LLCCompletedProven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
-
ShionogiCompletedGram-Negative InfectionSpain